Imaging Technology

SEPTEMBER 20, 2023

a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX biology-guided radiotherapy.

Pharmaceutical 99

Pharmaceutical Radiopharmaceuticals Radiation Diagnostic 99

Imaging Technology

JULY 9, 2024

Campione also joins the Blue Earth Diagnostics Ltd. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., Board of Directors.

Diagnostic 85

Diagnostic Radiopharmaceuticals Nuclear Medicine Magnetic Resonance Imaging 85

Imaging Technology

JUNE 15, 2023

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.

Radiopharmaceuticals 89

Radiopharmaceuticals Pharmaceutical Nuclear Medicine PET Scan 89

Imaging Technology

JANUARY 5, 2024

milla1cf Fri, 01/05/2024 - 11:32 January 5, 2024 — NorthStar Medical Radioisotopes, LLC , a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, and Curadh MTR Inc. Chief Executive Officer of NorthStar Medical Radioisotopes.

Radiopharmaceuticals 52

Radiopharmaceuticals Medical Nuclear Medicine Pharmaceutical 52

AuntMinnie

JULY 12, 2024

As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. At the time, their cancer center served a significant cancer population in the region and maintained robust and ever-expanding PET diagnostics.

Nuclear Medicine 105

Nuclear Medicine Radiation Oncology Radiopharmaceuticals Radiation 105

Imaging Technology

OCTOBER 11, 2023

-based company, to develop, manufacture and commercialize SOFIE’s Gallium-68 and Fluorine-18 labelled diagnostics targeting fibroblast activation protein (FAP). SOFIE will continue its clinical development and commercialization program with [18F]FAPI-74 in the U.S. Financial terms were not disclosed. Sherly Mosessian , Ph.D,

Healthcare 95

Healthcare Healthcare Pharmaceutical Radiopharmaceuticals 95

Imaging Technology

NOVEMBER 2, 2023

2] In addition to the potential benefits of these AI models in clinical use, with roughly 5,000 immunotherapies in development today [3] , selecting patients more likely to respond could also help drug developers to speed up and increase the likelihood of success of clinical trials.

Pharmaceutical 59

Pharmaceutical Healthcare Healthcare Clinic 59